This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== The cellular response to infection === Circulating hemocytes are key regulators of infection. This has been demonstrated both through genetic tools to generate flies lacking hemocytes, or through injecting microglass beads or lipid droplets that saturate hemocyte ability to phagocytose a secondary infection. Flies treated like this fail to phagocytose bacteria upon infection, and are correspondingly susceptible to infection. These hemocytes derive from two waves of hematopoiesis, one occurring in the early embryo and one occurring during development from larva to adult. However Drosophila hemocytes do not renew over the adult lifespan, and so the fly has a finite number of hemocytes that decrease over the course of its lifespan. Hemocytes are also involved in regulating cell-cycle events and apoptosis of aberrant tissue (e.g. cancerous cells) by producing Eiger, a tumor necrosis factor signalling molecule that promotes JNK signalling and ultimately cell death and apoptosis.
The production, distribution, and sale of cocaine products is restricted (and illegal in most contexts) in most countries as regulated by the Single Convention on Narcotic Drugs, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. In the United States the manufacture, importation, possession, and distribution of cocaine are additionally regulated by the 1970 Controlled Substances Act. Some countries, such as Bolivia, Colombia, and Peru, permit the cultivation of coca leaf for traditional consumption by the local indigenous population, but nevertheless, prohibit the production, sale, and consumption of cocaine. The provisions as to how much a coca farmer can yield annually is protected by laws such as the Bolivian Cato accord. In addition, some parts of Europe, the United States, and Australia allow processed cocaine for medicinal uses only.
== Similar species == The distinguishing features of Parmotrema perlatum, such as the presence of soredia and stictic acid, facilitate its easy identification. In mature specimens, the appearance of scattered, fine cracks on the upper surface may resemble the cracked maculae seen in P. reticulatum, which shares similar habitats. However, the two species can be differentiated chemically, as P. reticulatum contains salazinic acid, unlike P. perlatum. Parmotrema perlatum and Parmotrema stuppeum are two morphologically similar species that can be found in similar habitats. Both species have a loosely attached thallus with revolute, wavy lobes and sparsely ciliate lobe tips. Their upper cortex is continuous and not finely reticulately cracked, while the lower surface is black and rhizinate. Both species also feature linear soralia. However, there are several key differences that can help distinguish between the two. While earlier descriptions suggested that P. stuppeum has a matte, olive-green to brownish-green upper surface and P. perlatum has a slightly shiny, whitish-grey to greyish-green upper surface, recent observations have shown that both species have a distinctly matte upper surface with similar colouration. The most reliable morphological difference in the field is the location of the soralia: P. stuppeum has strictly terminal soralia, whereas P. perlatum has submarginal soralia. Additionally, the two species can be distinguished by their chemical composition. P. stuppeum contains salazinic acid, while P. perlatum has a stictic acid complex.
Corporate real estate Class A office space Commercial Information Exchange Estoppel certificate, a document used in International real estate Owner Occupied Commercial Real Estate Real estate Real estate investing Real estate economics
Conflict Analysis Resources Center. Archived from the original on July 4, 2007. Colombian-based private research center that studies the conflict (In Spanish and English) "Colombian Army website". Archived from the original on September 27, 2007. Retrieved February 24, 2006. (In Spanish and English) "Colombian President's Office". Archived from the original on November 18, 2008. Retrieved February 24, 2006. (In Spanish and English) "Background Note: Colombia". U.S. Department of State. Retrieved February 11, 2006. "Different Views of Colombian Territory". Retrieved February 24, 2006. Maps of the conflict. "AUC Official Website". Retrieved February 24, 2006. (in Spanish) "FARC website". Archived from the original on July 5, 2008. Retrieved July 12, 2008. (in Spanish and English) – No longer available online (censored by U.S. government) "Civil War? The Language of Conflict in Colombia" (PDF). Ideas for Peace Foundation. Archived from the original (PDF) on September 10, 2009. Retrieved February 24, 2006. (PDF) Is the Colombia conflict a civil war? "The Peace Village San José Must Live". SOS San Jose. Archived from the original on January 12, 2006. Retrieved February 24, 2006. (in German and English) "Washington Office on Latin America". Retrieved February 24, 2006. "Who Shot My Brother?". National Film Board of Canada. Archived from the original on May 24, 2007. Retrieved May 27, 2018. "Why the End of the Cold War Doesn't Matter: the US War of Terror in Colombia". Bristol University Politics Department. Archived from the original on October 1, 2005.
Sources: en.wikipedia.org
== Catabolism and clearance == The half-life of Lp(a) in circulation is approximately three to four days. The mechanism and sites of Lp(a) catabolism are largely unknown. The LDL receptor has been reported as a receptor for Lp(a) clearance, but is not a major pathway of Lp(a) metabolism under normal or hypercholesterolemic conditions. The kidney has been identified as playing a role in Lp(a) clearance from plasma.
Phytochemistry is the study of phytochemicals, which are chemicals derived from plants. Phytochemists strive to describe the structures of the large number of secondary metabolites found in plants, the functions of these compounds in human and plant biology, and the biosynthesis of these compounds. Plants synthesize phytochemicals for many reasons, including to protect themselves against insect attacks and plant diseases. The compounds found in plants are of many kinds, but most can be grouped into four major biosynthetic classes: alkaloids, phenylpropanoids, polyketides, and terpenoids. Phytochemistry can be considered a subfield of botany or chemistry. Activities can be led in botanical gardens or in the wild with the aid of ethnobotany. Phytochemical studies directed toward human (i.e. drug discovery) use may fall under the discipline of pharmacognosy, whereas phytochemical studies focused on the ecological functions and evolution of phytochemicals likely fall under the discipline of chemical ecology. Phytochemistry also has relevance to the field of plant physiology.
=== GPV / IIIa (GPV / IIa = integrin α5β1) === This is a heterodimer. Its α5 subunit is 36% identical to the GPIIb subunit. This complex is located mainly on endothelial cells but also on smooth muscle cells, macrophages and platelets. Its main function is in the adhesion of cells to the extracellular matrix components.
Minimal change disease is characterised as a cause of nephrotic syndrome without visible changes in the glomerulus on microscopy. Minimal change disease typically presents with edema, an increase in proteins passed from urine and decrease in blood protein levels, and an increase in circulating lipids (i.e., nephrotic syndrome) and is the most common cause of the nephrotic syndrome in children. Although no changes may be visible by light microscopy, changes on electron microscopy within the glomeruli may show a fusion of the foot processes of the podocytes lining the basement membrane of the capillaries of glomerulus. It is typically managed with corticosteroids and does not progress to chronic kidney disease.
Hasegawa, Shuichi; Levin, Christoph; Radner, Karen, eds. (2018). The Last Days of the Kingdom of Israel. Walter de Gruyter GmbH & Co KG. ISBN 978-3-11-056660-4. Joffe, Alexander H. (2002). "The Rise of Secondary States in the Iron Age Levant". Journal of the Economic and Social History of the Orient. 45 (4): 425–467. doi:10.1163/156852002320939311. JSTOR 3632872. McNutt, Paula (1999). Reconstructing the Society of Ancient Israel. Westminster John Knox Press. ISBN 978-0-664-22265-9. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Manzur, Ibn (1979). "SMR". Lisan al Arab. Vol. 21. Al-dar al-Misriya li-l-talif wa-l-taryamar. ISBN 978-0-866-85541-9. Mendels, D. (1987). The Land of Israel as a Political Concept in Hasmonean Literature: Recourse to History in Second Century B.C. Claims to the Holy Land. Texte und Studien zum antiken Judentum. J.C.B. Mohr. ISBN 978-3-16-145147-8. Retrieved 7 December 2020. Na'aman, Nadav (2011). "The Exodus Story: Between Historical Memory and Historiographical Composition". Journal of Ancient Near Eastern Religions. 11: 39–69. doi:10.1163/156921211X579579. Redmount, Carol A. (2001) [1998]. "Bitter Lives: Israel in and out of Egypt". In Coogan, Michael D. (ed.). The Oxford History of the Biblical World. Oxford and New York: Oxford University Press. pp. 58–89. ISBN 978-0-19-513937-2. Archived from the original on 3 April 2023. Retrieved 26 June 2023. Tetley, M. Christine (2005). The Reconstructed Chronology of the Divided Kingdom. Eisenbrauns. pp. 105–. ISBN 978-1-57506-072-9. Tubb, Jonathan N. (1998). Canaanites.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.